Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell-induced killer cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Hornetcorn Bio-technology
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous dendritic cell-induced killer (DIK) cells is an experimental adoptive cell therapy being developed by Jiangsu Decon Bio-Sci-Technology Co. Ltd. for the treatment of middle and advanced stage non-small cell lung cancer (NSCLC). The therapy involves the isolation of a patient's own immune cells, specifically dendritic cells (DCs) and killer cells (often cytokine-induced killer cells), which are co-cultured to enhance the tumor-killing capacity of the effector cells. These DIK cells are then reinfused into the patient to stimulate a targeted anti-tumor immune response. This approach combines the potent antigen-presenting capabilities of dendritic cells with the direct cytotoxic activity of killer cells to overcome tumor-induced immunosuppression.
- Other names
- autologous DIK cellsdendritic cell-induced killer cells
Beyond the preview
Go deeper on autologous dendritic cell-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell-induced killer cells.